Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX2105 Phase 1 Study in Healthy Chinese Subjects
NCT06537050Phase 1Enrolling by invitation
- Sponsor
- Jingxin Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JX2105 in Parkinson's disease (PD) (5 arms), sponsored by Jingxin Pharmaceutical. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events. Started Jul 2024; status: enrolling by invitation.
02
Drugs
JX2105
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06537050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537050.